NCT07556653 Allogeneic WTX-212C in Advanced Solid Tumors
| NCT ID | NCT07556653 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Zhejiang Provincial People's Hospital |
| Condition | Advanced Solid Tumors |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2026-06-26 |
| Primary Completion | 2027-04-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 24 participants in total. It began in 2026-06-26 with a primary completion date of 2027-04-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a multicenter, open-label, single-arm Phase I study to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of allogeneic WTX-212C, an investigational allogeneic engineered red blood cell (RBC)-based product, in patients with advanced solid tumors who have failed standard therapies or have no available standard treatment options. The study consists of a dose-escalation phase using a 3+3 design followed by a dose-expansion phase. Participants will receive allogeneic WTX-212C via intravenous infusion. Tumor assessments will be performed every 6 weeks according to RECIST 1.1.
Eligibility Criteria
Inclusion Criteria: * Age 18-75 years * Histologically or cytologically confirmed advanced solid tumors * At least one measurable lesion per RECIST 1.1 * ECOG performance status ≤1 * Adequate organ function * Life expectancy ≥12 weeks Exclusion Criteria: * Uncontrolled serious medical conditions * Active or uncontrolled infections * Symptomatic or unstable CNS metastases * History of severe hypersensitivity to biologic agents * Autoimmune diseases requiring systemic treatment * Prior severe immune-related adverse events * Conditions affecting red blood cell integrity
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07556653 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Advanced Solid Tumors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07556653 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07556653 currently recruiting?
Yes, NCT07556653 is actively recruiting participants. Contact the research team at Yangliuqq2003@163.com for enrollment information.
Where is the NCT07556653 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT07556653 clinical trial?
NCT07556653 is sponsored by Zhejiang Provincial People's Hospital. The trial plans to enroll 24 participants.